| Literature DB >> 35079474 |
Norito Fukuda1, Masakazu Ogiwara1, Satoshi Nakata2, Mitsuto Hanihara1, Tomoyuki Kawataki1, Masataka Kawai3, Sumihito Nobusawa2, Hideaki Yokoo2, Hiroyuki Kinouchi1.
Abstract
A typical teratoid/rhabdoid tumors (AT/RT) are highly malignant embryonal tumors in children that are associated with inactivation of the integrase interactor 1 (INI1) gene. Several adult cases of AT/RT have been reported, which were characterized by the sellar occurrence and predominantly occurred in females with INI1 mutation variants. However, clinical and genetic features are poorly understood in this unusual entity. We experienced a case of a 45-year-old female with sellar AT/RT presenting diplopia, who underwent subtotal removal of the tumor by the endoscopic endonasal transsphenoidal approach. Pathological diagnosis was AT/RT with INI1 inactivation on immunohistochemistry. Subsequently, multiple lung metastases were confirmed on fluorodeoxyglucose positron emission tomography (FDG-PET). Although she received postoperative chemoradiotherapy, she died of cerebrospinal fluid dissemination. Autopsy revealed cerebrospinal dissemination and lung metastasis of AT/RT. Biallelic alterations in the INI1 gene were identified by direct sequencing, harboring on different alleles (compound heterozygous mutations) was observed, which is the potential genetic pattern in adult AT/RT. Literature review indicated that lung metastasis frequently occurs in sellar AT/RTs, which is accompanied by cavernous sinus invasion. These observations suggested that cavernous sinus invasion causes haematogenous metastasis to the lung in sellar AT/RT. We discuss clinical and pathological features in adult sellar AT/RT to improve understanding of this unique entity.Entities:
Keywords: INI1; adult AT/RT; compound heterozygous mutation; lung metastasis; staghorn appearance
Year: 2021 PMID: 35079474 PMCID: PMC8769414 DOI: 10.2176/nmccrj.cr.2020-0128
Source DB: PubMed Journal: NMC Case Rep J ISSN: 2188-4226
Fig. 1Coronal T1-weighted MR images with contrast enhancement before (A) and after (B) surgery. Two weeks after surgery, the enhancing mass lesion was increased (C). After initial chemoradiation therapy, the enhancing mass lesion was decreased (D). An enhanced CT image (E) showed several nodular metastases in axial slices of both lungs (yellow arrowheads). Sagittal T1-weighted spinal MR images (F, G) revealed an enhanced mass lesion at the Th2 level (arrow, F). The surface of the spinal cord was almost enhanced, suggesting cerebrospinal fluid dissemination (white arrowheads, G). Bone metastasis was seen at the L4-5 spinous process (yellow arrowhead, G). After ICE therapy, the metastatic lung lesion and cerebrospinal fluid dissemination were decreased (yellow arrowheads H, arrow I, white arrowheads J). FDG-PET (K) showed accumulation in the lung tumor (arrow and circle). Hilar lymph node also showed increased accumulation (square). CT: computed tomography, FDG-PET: fluorodeoxyglucose positron emission tomography, ICE: ifosfamide, cisplatin, and etoposide, MR: magnetic resonance.
Fig. 2Photomicrographs of the tumor. (A and B) The tumor was predominantly composed of dense, diffuse proliferation of small- to medium-sized cells with vesicular nuclei that had prominent nucleoli. Thin-walled branching vessels were observed (A). Rare rhabdoid cells were admixed within (B). (C) Immunohistochemistry. Tumor cells were negative for INI1, whereas endothelial cells were positive for INI1 as an internal control (C). (D–F) Systemic pathological autopsy. The tumor could be seen in the lung (red arrow) (D). Metastasis of sellar AT/RT (E) and vascular invasion (F) were detected in lung pathology. Haematoxylin and eosin staining (A, B, E, F). Original magnification: A, C, D, F: 100×; B, E: 400×. AT/RT: atypical teratoid/rhabdoid tumors.
Fig. 3Molecular genetic analyses. (A) Multiplex ligation-dependent probe amplification analysis revealed that there are no copy number changes in the INI1 gene and flanking genes. (B) Sanger sequencing detected two different coding sequence mutations; one mutation was c.144 delC in exon 2, and the other mutation was c.819_820 insT in exon 7.
Clinical and pathological characteristics of sellar atypical teratoid/rhabdoid tumor
| Authors and year | Age (years), sex | Surgery | Radiation | Chemotherapy | Cavernous invasion | Metastatic site | Autopsy | Survival (month) | |
|---|---|---|---|---|---|---|---|---|---|
| Kuge A et al., 2000[ | 31, F | Subtotal | Local, posterior fossa | 1st: CDDP + VP-16, 2nd: MTX | − | − | − | 28 | NA |
| Raisanen J et al., 2005[ | 20, F | No detail | Yes (no detail) | Yes (No detail) | NA | − | − | Alive at 28 | c.118 delC (exon2) |
| Raisanen J et al., 2005[ | 31, F | No detail | Yes (no detail) | NA | NA | − | − | 9 | NA |
| Arita K et al., 2008[ | 56, F | Subtotal | SRS, local, spine | No | + | Spinal cord | − | 23 | c.370_371 delA (exon4) + c.528_529 delC (exon5) |
| Las Heras F et al., 2010[ | 46, F | No detail | NA | NA | NA | − | − | Not described | NA |
| Schneiderhan et al., 2011[ | 61, F | Total | NA | NA | − | − | − | 3 | c.91G>T p. (Glu31) (exon 1) + c.538_563 del p. (Ala 180Hisfs22) (exon 5) |
| Schneiderhan et al., 2011[ | 57, F | No detail | Yes (no detail) | ADM+CDDP | + | − | − | Alive at 6 | NA |
| Moretti C et al., 2013[ | 60, F | Subtotal | Local | 1st: ADM + VNB 2nd: CBDCA | + | Lung | − | 30 | NA |
| Park HG et al., 2014[ | 42, F | Subtotal | Craniospinal | Multiagent | + | − | − | Alive at 24 | NA |
| Shitara S et al., 2014[ | 44, F | Partial | Yes (no detail) | ICE | + | Spinal cord, lung | − | 17 | No aberrations |
| Biswas S et al., 2015[ | 48, F | Total | No | VDC, ICE | NA | − | − | Died | c.146C>G (exon2) + c.629+2T>G (intron5) |
| Nobusawa S et al., 2016[ | 69, F | Subtotal | Local | TMZ | + | − | − | Alive at 37 | c.795 + 1 delG (intron6) + c.150 dupC p. (Trp51Leufs20) (exon2) |
| Nakata S et al., 2017[ | 26, F | No detail | Local, spine | 1st: MTX, 2nd: ICE | NA | − | − | 33 | c.544C>T (exon5) + c.681_697del (exon6) |
| Nakata S et al., 2017[ | 21, F | No detail | Local | ICE | NA | − | − | 35 | No aberrations |
| Almalki MH et al., 2017[ | 36, F | Total | Local | ICE | + | − | − | Alive at 37 | NA |
| Johann PD et al., 2018[ | 66, M | No detail | NA | NA | NA | − | − | Alive at 54 | No aberrations |
| Johann PD et al., 2018[ | 20, F | No detail | NA | NA | NA | − | − | 120 | c.118 delC p. (Arg40Glufs16) (exon2) |
| Johann PD et al., 2018[ | 48, F | No detail | NA | NA | NA | − | − | Alive at 4 | No aberrations |
| Johann PD et al., 2018[ | 46, F | No detail | NA | NA | NA | − | − | 0 | c.818_886 del p. (Ile273_Leu295del) (exon7) |
| Nishikawa A et al., 2018[ | 42, F | Total | Local | Paclitaxel | + | Spinal cord | Systemic | 11 | c.592T>C (p.Gln198x) |
| Paolini MA et al., 2018[ | 31, F | Subtotal | No | No | NA | − | − | 2 | SMARCB1 homozygous deletion |
| Paolini MA et al., 2018[ | 36, F | Subtotal | Yes (no detail) | Yes (No detail) | NA | − | − | Alive at 22 | c.785del, p.V262AfsX5 |
| Paolini MA et al., 2018[ | 47, F | Subtotal | Local | Yes (3 agent) | NA | − | − | Alive at 62 | c.472C>T, p.R158X |
| Paolini MA et al., 2018[ | 65, F | Subtotal | Local | Yes (4 agent) | NA | Spinal cord | − | 23 | c.773C>A, p.S258X |
| Present | 45, F | Subtotal | Local, lung | 1st: TMZ, 2nd: ICE | + | Lung, spinal cord, bone | Systemic | 5 | c.144 delC (exon2) + c.819_820 insT (exon7) |
NA: not assessed.